Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects With Multiple System Atrophy (M-STAR Study)

NCT03952806 is registered in ClinicalTrials.gov with Biohaven Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03952806
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03952806 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects With Multiple System Atrophy (M-STAR Study)
Lead sponsor
Biohaven Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
July 29, 2019
Completion date
June 30, 2022
Enrollment
421 (actual)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

multiple system atrophy